Reglan Tardive Dyskinesia Settlement: Claim Valuation Factors Overview

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health to Occupational Exposure

The legacy of general health and science information provides a foundational understanding of how the human body responds to various pharmaceutical interventions. Within this broad context, the transition from a general wellness perspective to a specific occupational exposure concern requires a focused pivot. In mass production environments, workers may encounter a range of chemical agents and prescribed medications as part of their medical care. One such medication, metoclopramide, commonly known by the brand name Reglan, is used to treat gastrointestinal disorders. However, its long-term use has been associated with a serious neurological condition. The shift from a general health information framework to an occupational exposure concern is marked by the need to evaluate the specific risks faced by employees who are prescribed this medication over extended periods. This evaluation is critical in industrial settings where workforce health management must account for the potential development of movement disorders. The bridge between general health literacy and the targeted assessment of Reglan exposure in the workplace is built on the recognition that prolonged use of certain drugs can lead to adverse outcomes, thereby necessitating a careful review of claim valuation factors for those affected.

Medical Evidence and Risk Factors

Reglan (metoclopramide) is associated with tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk of developing TD increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the FDA requires a boxed warning stating that metoclopramide can cause TD, a serious movement disorder that may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum treatment duration is 12 weeks; for diabetic gastroparesis, treatment should also not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation of TD includes involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist after drug discontinuation. Metoclopramide may also partially suppress TD signs, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway involves dopamine receptor blockade in the basal ganglia, leading to supersensitivity and abnormal motor control. Risk factors include elderly age, female sex, diabetes, liver or kidney failure, and concomitant use of antipsychotic drugs, which lower the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). Incidence estimates vary. A real-world epidemiology study (2011-2020) using the MarketScan database analyzed TD rates among metoclopramide-treated gastroparesis patients compared to untreated patients and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). Another review found the risk of TD from metoclopramide to be low, approximately 0.1% per 1000 patient-years, far below earlier estimates of 1%-10% cited in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, the FDA boxed warning emphasizes that risk increases with duration and cumulative dose, and that TD can be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Settlement Valuation Factors

Adequacy of warnings is a key factor in settlement considerations. The boxed warning explicitly states the risk of TD, the need for shortest treatment duration, and contraindication in patients with prior TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite this, many patients may have been prescribed Reglan for longer than recommended periods, increasing exposure. Settlement valuation for affected patients typically considers the severity and irreversibility of TD, duration of Reglan use, presence of risk factors, and the timeline between exposure and documented harm. The timeline is critical: TD may develop months or years after starting metoclopramide, and symptoms can persist or worsen after discontinuation. Patients with prolonged use beyond 12 weeks, especially those with diabetes or elderly females, may have stronger claims due to higher risk (https://pubmed.ncbi.nlm.nih.gov/31050085/). In settlement contexts, factors such as medical records documenting TD diagnosis, duration of Reglan therapy, and evidence of inadequate monitoring or failure to discontinue upon symptom onset are important. The FDA advises immediate discontinuation of Reglan if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to follow this guidance may strengthen a patient's claim. Additionally, the boxed warning states that Reglan should be used for the shortest duration and that the need for continued treatment should be periodically reassessed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Non-adherence to these recommendations could be relevant in settlement negotiations. Overall, settlement valuation for Reglan-related TD claims involves a complex assessment of medical evidence, risk factors, warning adequacy, and the temporal relationship between drug exposure and harm. Patients with documented TD after prolonged Reglan use, particularly those in high-risk groups, may have stronger claims. However, the relatively low incidence of TD in recent studies (https://pubmed.ncbi.nlm.nih.gov/31050085/) may influence settlement amounts. Legal and medical professionals should carefully evaluate each case based on individual circumstances and the available evidence.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is tardive dyskinesia and how is it linked to Reglan?

Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. Reglan (metoclopramide) is associated with TD, and the FDA requires a boxed warning stating that metoclopramide can cause TD, which may be irreversible. The risk increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What factors influence the valuation of a Reglan TD claim?

Settlement valuation for Reglan-related TD claims typically considers the severity and irreversibility of TD, duration of Reglan use, presence of risk factors (e.g., elderly age, female sex, diabetes), and the timeline between exposure and documented harm. Adequacy of warnings and failure to discontinue upon symptom onset are also important factors (https://pubmed.ncbi.nlm.nih.gov/31050085/).

How long can Reglan be safely used?

For patients with symptomatic gastroesophageal reflux, the maximum treatment duration is 12 weeks; for diabetic gastroparesis, treatment should also not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.